<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148627</url>
  </required_header>
  <id_info>
    <org_study_id>15164</org_study_id>
    <secondary_id>I7P-MC-DSAA</secondary_id>
    <nct_id>NCT02148627</nct_id>
  </id_info>
  <brief_title>Safety Study of LY3041658 in Healthy Participants</brief_title>
  <official_title>A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3041658 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of LY3041658 in healthy
      participants, including first generation Japanese. The study will also investigate how the
      drug is processed and affects key immune cells. Study participation will last 4 months.

      Protocol amended in January, 2016 to include first generation Japanese participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2014</start_date>
  <completion_date type="Actual">February 11, 2017</completion_date>
  <primary_completion_date type="Actual">February 11, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants with One or More Drug-Related Adverse Events</measure>
    <time_frame>Baseline to study completion (Day 85)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY3041658</measure>
    <time_frame>Predose through Day 85, at specified timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of Last Measurable Concentration (tlast)</measure>
    <time_frame>Predose through Day 85, at specified timepoints</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3041658 (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3041658, administered as a slow intravenous (IV) infusion in escalating dose cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3041658 (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3041658 administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo (0.9% sodium chloride injection) administered as a slow IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3041658 (SC)</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3041658 (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3041658 (IV)</intervention_name>
    <description>Administered as slow IV infusion</description>
    <arm_group_label>LY3041658 (IV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as slow IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All:

               -  Body mass index (BMI) between 18.0 to 32.0 kilogram per square meter (kg/m²).

               -  Absolute neutrophil count at screening should be ≥1.8 and ≤7.2 x 10^3/microliter
                  (uL), inclusive.

          -  First-generation Japanese:

               -  Participant, biological parents, and biological grandparents must be of exclusive
                  Japanese descent and born in Japan.

               -  Are 20 to 65 years of age, inclusive, at the time of initial screening.

        Exclusion Criteria:

        - Have received antibody-based biologic agents (marketed or investigational) within 3
        months or 5 half lives (t1/2) of the drug (whichever is longer) prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Early Phase Unit at Glendale</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>90216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAREXEL-Phase 1 Baltimore Harbor Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibody</keyword>
  <keyword>autoimmune</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

